Intensity Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTS research report →
About the company
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials.
- CEO
- Lewis H. Bender
- IPO
- 2023
- Employees
- 5
- HQ
- Westport, CT, US
Price Chart
- Market Cap
- $8.00M
- P/E
- -0.61
- P/S
- 0.00
- P/B
- 10.77
- EV/EBITDA
- 0.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -136.82%
- ROIC
- -110.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-11,606,000 · 28.66%
- EPS
- $-8.56 · 70.74%
- Op Income
- $-11,972,000
- FCF YoY
- 39.34%
- 52W High
- $43.50
- 52W Low
- $3.51
- 50D MA
- $4.48
- 200D MA
- $7.57
- Beta
- 3.06
- Avg Volume
- 40.58K
Get TickerSpark's AI analysis on INTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Wesolowski John M | other | 3,688 |
| Jun 30, 26 | Talamo Joseph | other | 1,093 |
| Mar 26, 26 | BENDER LEWIS H | other | 37,749 |
| Dec 31, 25 | Wesolowski John M | other | 8,918 |
| Dec 31, 25 | Talamo Joseph | other | 14,482 |
| Jun 30, 25 | Wesolowski John M | other | 69,745 |
| Jun 30, 25 | Talamo Joseph | other | 14,179 |
| May 2, 25 | DUBIN THOMAS I H | other | 50,000 |
| May 2, 25 | Donovan Daniel | other | 50,000 |
| May 2, 25 | GOLDBERG MARK A | other | 50,000 |
Our INTS coverage
Recent articles, reports, and earnings notes.
No research on INTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INTS report →Similar companies
Peers in the same neighborhood.